- Home
- Blog
- News
- Basics
- Sources
- Agencies, Regulatory & Organisations
- CERSI Excipients Browser
- Excipient Report
- Excipient DMF List
- EXCiPACT Certified Companies
- Excipient Documentation
- Excipient EINECS Numbers
- Excipient E-Numbers
- FDA Inactive Ingredient List
- FDA GRAS Substances (SCOGS) Database
- IPEC Americas
- USP - U.S. Pharmacopeia
- Definitions
- Whitepapers / Publications
- Supplier
- Services
- Media
- Events
- 1st pharmaexcipients Poster Award
- Event Calendar
- Events featured by pharma-excipients
- 4th Annual Formulation & Drug Delivery Congress
- DDF Summit
- ExcipientFest Americas
- ExcipientFest Asia
- Global CompliancePanel
- International Conference and Exhibition on Pharmaceutics & Novel Drug Delivery Systems
- Formulation & Drug Delivery USA Congress
- Laboratory Medicine 2018
- Making Pharmaceuticals Europe
- Making Pharmaceuticals Exhibition
- Pharma Integrates
- PharmaExcipients China @CPhI China
- TTC Technology Training Center
- Jobs
- Online Sourcing
- Contact
07. June 2016
Purpose Currently, the FDA allows biowaivers for Class I (high solubility and high permeability) and Class III (high solubility and low permeability) compounds of the Biopharmaceutics Classification System (BCS). Scientific evidence should be provided to support biowaivers for BCS Class I and Class III (high solubility and low permeability) compounds.
03. April 2016
Microcontainers with an inner diameter of 223 μm are fabricated using the polymer SU-8, and evaluated in vitro, in situ and in vivo for their application as an advanced oral drug delivery system for the poorly water soluble drug furosemide. An amorphous sodium salt of furosemide (ASSF) is filled into the microcontainers followed by applying a lid using Eudragit L100. It is possible to control the drug release in vitro, and in vitro absorption studies show that the microcontainers are not a...